Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Kie Uchii"'
Autor:
Shotaro Kamata, Akihiro Honda, Ryo Ishikawa, Makoto Akahane, Ayane Fujita, Chihiro Kaneko, Saeka Miyawaki, Yuki Habu, Yui Shiiyama, Kie Uchii, Yui Machida, Takuji Oyama, Isao Ishii
Publikováno v:
Antioxidants, Vol 12, Iss 8, p 1523 (2023)
No therapeutic drugs are currently available for nonalcoholic steatohepatitis (NASH) that progresses from nonalcoholic fatty liver via oxidative stress-involved pathways. Three cognate peroxisome proliferator-activated receptor (PPAR) subtypes (PPAR
Externí odkaz:
https://doaj.org/article/0accaf46209a47e383198c9c9eddc003
Autor:
Takuji Oyama, Chihiro Satta, Ayane Nemoto, Isao Ishii, Kazuki Terasawa, Kie Uchii, Shotaro Kamata, Yui Machida, Akihiro Honda
Publikováno v:
Biologicalpharmaceutical bulletin. 44(9)
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptor-type transcription factors that consist of three subtypes (α, γ, and β/δ) with distinct functions and PPAR dual/pan agonists are expected to be the next generation of drugs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f1374982f0a397b94d4e2e76752d365
https://pubmed.ncbi.nlm.nih.gov/34471049
https://pubmed.ncbi.nlm.nih.gov/34471049
Autor:
Akihiro Honda, Shotaro Kamata, Makoto Akahane, Yui Machida, Kie Uchii, Yui Shiiyama, Yuki Habu, Saeka Miyawaki, Chihiro Kaneko, Takuji Oyama, Isao Ishii
Publikováno v:
International Journal of Molecular Sciences; Volume 23; Issue 9; Pages: 4726
Among the agonists against three peroxisome proliferator-activated receptor (PPAR) subtypes, those against PPARα (fibrates) and PPARγ (glitazones) are currently used to treat dyslipidemia and type 2 diabetes, respectively, whereas PPARδ agonists a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::196f483a2103b944b741ea6f86d2a448
https://doi.org/10.3390/ijms23094726
https://doi.org/10.3390/ijms23094726